The particularities of hemostasis in patients with non-ST elevation myocardial infarction and some comorbidities


  • Tatiana DANILĂ IMSP Institutul de Cardiologie
  • Lucia CIOBANU IMSP Institutul de Cardiologie
  • Mihaela MUNTEANU IMSP Institutul de Cardiologie



Hemostasis, NSTEMI, diabetes, coagulation, dyslipidemia


The formation of an obstructive thrombus within an artery remains a major cause of mortality and morbidity worldwide. [1] Despite effective inhibition of platelet function by modern antiplatelet therapies, these agents fail to fully eliminate atherothrombotic risk. This may well be related to extensive vascular disease, beyond the protective abilities of the treatment agents used. However, recent evidence suggests that residual vascular risk in those treated with modern antiplatelet therapies is related, at least in part, to impaired fibrin clot lysis.Along these lines, thrombosis is the result of several changes in local homeostasis: endothelial dysfunction, changes in the fibrinolytic system, increased content of some coagulation factors, decreased natural inhibitors, platelet hyperactivity [2] [3].In this review, we attempt to shed more light on the role of hypofibrinolysis in predisposition to arterial vascular events. We provide a brief overview of the coagulation system followed by addressing the role of impaired coagulation, anticoagulation, and fibrinolysis in acute vascular conditions, including coronary artery disease.We also discuss the prognostic implications of coagulation biomarkers regarding arterial thrombotic events, addressing, in particular, people who are exposed to metabolic risks (hyperlipidemia, hypertension, and diabetes).We conclude that affecting coagulation appears to contribute to residual thrombosis risk in individuals with arterial disease on antiplatelet therapy, and targeting proteins in the fibrinolytic and coagulant system represents a viable strategy to improve outcomes in this population. Future work is required to refine the antithrombotic approach by modulating pathological abnormalities in the fibrinolytic and anticoagulant system and tailoring the therapy according to the need of each individual.

Author Biographies

Tatiana DANILĂ, IMSP Institutul de Cardiologie

cercetător științific

Lucia CIOBANU, IMSP Institutul de Cardiologie

doctor habilitat în științe medicale, conf. cercetător

Mihaela MUNTEANU, IMSP Institutul de Cardiologie

doctor în științe medicale, cercetător științific


E. L. Hethershaw et al., “The effect of blood coagulation factor XIII on fibrin clot structure and fibrinolysis,” J. Thromb. Haemost., vol. 12, no. 2, pp. 197–205, Feb. 2014, doi: 10.1111/JTH.12455.

J. Palasubramaniam, X. Wang, and K. Peter, “Myocardial Infarction From Atherosclerosis to Thrombosis: Uncovering New Diagnostic and Therapeutic Approaches,” Arterioscler. Thromb. Vasc. Biol., vol. 39, no. 8, pp. E176–E185, 2019, doi: 10.1161/ATVBAHA.119.312578.

E. Fuentes, R. Moore-Carrasco, A. Marcus, A. Paes, and A. Trostchansky, “Role of Platelet Activation and Oxidative Stress in the Evolution of Myocardial Infarction”, doi: 10.1177/1074248419861437.

R. H. Olie, P. E. J. van der Meijden, and H. ten Cate, “The coagulation system in atherothrombosis: Implications for new therapeutic strategies,” Res. Pract. Thromb. Haemost., vol. 2, no. 2, pp. 188–198, Apr. 2018, doi: 10.1002/RTH2.12080.

A. J. Reininger et al., “A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques,” J. Am. Coll. Cardiol., vol. 55, no. 11, pp. 1147–1158, Mar. 2010, doi: 10.1016/J.JACC.2009.11.051.

D. Stegner and B. Nieswandt, “Platelet receptor signaling in thrombus formation,” J. Mol. Med. (Berl)., vol. 89, no. 2, pp. 109–121, Feb. 2011, doi: 10.1007/S00109010-0691-5.

S. Yakovlev, E. Makogonenko, N. Kurochkina, W. Nieuwenhuizen, K. Ingham, and L. Medved, “Conversion of fibrinogen to fibrin: Mechanism of exposure of tPAand plasminogen-binding sites,” Biochemistry, vol. 39, no. 51, pp. 15730–15741, Dec. 2000, doi: 10.1021/bi001847a.

C. Longstaff and K. Kolev, “Basic mechanisms and regulation of fibrinolysis,” J. Thromb. Haemost., vol. 13 Suppl 1, no. S1, pp. S98–S105, Jun. 2015, doi: 10.1111/JTH.12935.

Y. H. Kim et al., “Comparison of Clinical Outcomes after Non-ST-Segment and ST-Segment Elevation Myocardial Infarction in Diabetic and Nondiabetic Populations,” J. Clin. Med., vol. 11, no. 17, p. 5079, Sep. 2022, doi: 10.3390/JCM11175079/S1.

E. E. Babes et al., “diagnostics Value of Hematological and Coagulation Parameters as Prognostic Factors in Acute Coronary Syndromes,” vol. 11, p. 850, 2021, doi: 10.3390/diagnostics11050850.

K. Kearney, D. Tomlinson, K. Smith, and R. Ajjan, “Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk,” Cardiovasc. Diabetol. 2017 161, vol. 16, no. 1, pp. 1–17, Mar. 2017, doi: 10.1186/ S12933-017-0515-9.

R. C. Sagar, K. M. Naseem, and R. A. Ajjan, “Antiplatelet therapies in diabetes,” Diabet. Med., vol. 37, no. 5, pp. 726–734, May 2020, doi: 10.1111/DME.14291.

B. M. Psaty et al., “Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study,” Arch. Intern. Med., vol. 161, no. 9, pp. 1183–1192, 2001, doi: 10.1001/ARCHINTE.161.9.1183.

A. Frattola, G. Parati, C. Cuspidi, F. Albini, and G. Mancia, “Prognostic value of 24-hour blood pressure variability,” J. Hypertens., vol. 11, no. 10, pp. 1133–1137, 1993, doi: 10.1097/00004872-199310000-00019.

K. Konstantinou et al., “Hypertension and patients with acute coronary syndrome: Putting blood pressure levels into perspective,” J. Clin. Hypertens., vol. 21, no. 8, pp. 1135–1143, Aug. 2019, doi: 10.1111/JCH.13622.

A. R. da Silva, R. A. Fraga-Silva, N. Stergiopulos, F. Montecucco, and F. Mach, “Update on the role of angiotensin in the pathophysiology of coronary atherothrombosis,” Eur. J. Clin. Invest., vol. 45, no. 3, pp. 274–287, Mar. 2015, doi: 10.1111/ECI.12401.

T. M. Kolettis, M. Barton, D. Langleben, and Y. Matsumura, “Endothelin in coronary artery disease and myocardial infarction,” Cardiol. Rev., vol. 21, no. 5, pp. 249–256, Sep. 2013, doi: 10.1097/CRD.0B013E318283F65A.

G. Santulli et al., “G protein-coupled receptor kinase 2 in patients with acute myocardial infarction,” Am. J. Cardiol., vol. 107, no. 8, pp. 1125–1130, Apr. 2011, doi: 10.1016/J.AMJCARD.2010.12.006.

S. Julius, “Corcoran Lecture. Sympathetic hyperactivity and coronary risk in hypertension,” Hypertens. (Dallas, Tex. 1979), vol. 21, no. 6 Pt 2, pp. 886–893, 1993, doi: 10.1161/01.HYP.21.6.886.

C. Catena, G. L. Colussi, G. Brosolo, and L. A. Sechi, “A prothrombotic state is associated with early arterial damage in hypertensive patients,” J. Atheroscler. Thromb., vol. 19, no. 5, pp. 471–478, 2012, doi: 10.5551/JAT.10819.

M. El Haouari and J. A. Rosado, “Platelet function in hypertension,” Blood Cells. Mol. Dis., vol. 42, no. 1, pp. 38–43, Jan. 2009, doi: 10.1016/J.BCMD.2008.07.003.

R. Vergallo et al., “Endothelial shear stress and coronary plaque characteristics in humans: combined frequency-domain optical coherence tomography and computational fluid dynamics study,” Circ. Cardiovasc. Imaging, vol. 7, no. 6, pp. 905–911, Nov. 2014, doi: 10.1161/CIRCIMAGING.114.001932.

D. A. Sica, “The importance of the sympathetic nervous system and systolic hypertension in patients with hypertension: Benefits in treating patients with increased cardiovascular risk,” Blood Press. Monit., vol. 5, no. SUPPL. 2, 2000, doi: 10.1097/00126097-200010002-00005.

L. Langouche et al., “Intensive insulin therapy protects the endothelium of critically ill patients,” J. Clin. Invest., vol. 115, no. 8, p. 2277, Aug. 2005, doi: 10.1172/JCI25385.

J.-P. Després et al., “Hyperinsulinemia as an independent risk factor for ischemic heart disease,” N. Engl. J. Med., vol. 334, no. 15, pp. 952–958, Apr. 1996, doi: 10.1056/NEJM199604113341504.

M. Muneeb et al., “Patterns of Dyslipidemia Among Acute Coronary Syndrome (ACS) Patients at a Tertiary Care Hospital in Lahore, Pakistan,” Cureus, vol. 14, no. 12, Dec. 2022, doi: 10.7759/CUREUS.32378.

M. Yang and A. Kholmukhamedov, “Platelet reactivity in dyslipidemia: Atherothrombotic signaling and therapeutic implications,” Rev. Cardiovasc. Med., vol. 22, no. 1, pp. 67–81, Mar. 2021, doi: 10.31083/J.RCM.2021.01.256/RCM2020256/FIG3.PNG.

K. Fujisue and K. Tsujita, “Current status of lipid management in acute coronary syndrome,” J. Cardiol., vol. 70, no. 2, pp. 101–106, 2017, doi: 10.1016/j.jjcc.2017.02.004.





Research Article